Parents in the United States who want to vaccinate their young children against Covid-19 this fall may face a growing set of ...

Moderna's candidate COVID-19 vaccine is even more effective than Pfizer's, trial results show, a "light at the end of the tunnel" for the pandemic.

Under Robert F. Kennedy Jr., federal officials may withdraw an endorsement for the vaccine in younger children.

Investors were seemingly buoyed by Moderna's vaccine trial results, with U.S. stock futures on Monday pointing to a strong opening. Dow futures were up 476 points, or 1.6%, before the start of ...

In the Moderna trial, 90 of the first 95 participants to develop COVID-19 had received the placebo and only five the active vaccine, so it was 94.5% effective. Results from another 56 ...

A second coronavirus vaccine has now joined the fight against COVID-19 in the United States. On December 18, the U.S. Food and Drug Administration authorized Moderna’s vaccine for emergency ...

Moderna also announced that it has initiated a submission to the FDA for emergency use authorization of the company’s Covid-19 vaccine for children ages 6 through 11 years old. Children that age ...

COVID vaccine maker Pfizer Inc. lost 0.6%, while its partner BioNTech, shed 3.8%. Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released.

Moderna’s Covid Vaccine: What You Need to Know Denise Grady Published Nov. 16, 2020 Updated Nov. 30, 2020 Share full article ...

Kennedy Jr. canceled nearly half a billion dollars’ worth of grants and contracts for mRNA-vaccine research.With Kennedy leading HHS, this about-face is easy to parse as yet another anti-vaccine move.

A second experimental COVID-19 vaccine — this one from Moderna — yielded extraordinarily strong early results Monday, another badly needed dose of hope as the pandemic enters a terrible new ...